Peggy Scherle, Chief Scientific Officer at Prelude Therapeutics Inc (PRLD), sold 19,800 shares at $41.14 ($808K) on 2021-05-07, disclosed to the SEC on 2021-05-11.
Open-market sale of $808k PRLD by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $40.30 | 3,964 | $160K | 19.8% |
| 2 | $40.30 | 3,964 | $160K | 19.8% |
| 3 | $41.14 | 5,836 | $240K | 29.7% |
| 4 | $41.14 | 5,836 | $240K | 29.7% |
| 5 | $41.85 | 200 | $8K | 1.0% |
| Total | $40.81 avg | 19,800 |
| $808K |
| 100% |
| Filing → |
| PRLD | SELL | 2021-07-29 | $709K | — | Filing → |
| PRLD | SELL | 2021-04-15 | $296K | — | Filing → |
| PRLD | SELL | 2021-04-09 | $1.2M | — | Filing → |